Management of fungal infections following allogeneic stem cell transplantation

References

• Bearman S, Appelbaum FR, Buckner C et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J. Clin. Oncol.6, 1562–1568 (1988).
   PubMed Web of Science ®Google Scholar
• Maris MB, Niederwieser D, Sandmaier BM et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood102(6), 2021–2030 (2003).
   PubMed Web of Science ®Google Scholar
• Steinbrook R. The cord-blood-bank controversies. N. Engl. J. Med.351(22), 2255–2257 (2004).
   PubMed Web of Science ®Google Scholar
• Wingard JR. Fungal infections after bone marrow transplant. Biol. Blood Marrow Transplant.5(2), 55–68 (1999).
   PubMedGoogle Scholar
• Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin. Infect. Dis.20(1), 115–125 (1995).
   PubMed Web of Science ®Google Scholar
• Kami M, Machida U, Okuzumi K et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br. J. Haematol.117(1), 40–46 (2002).
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis.34(7), 909–917 (2002).
   PubMed Web of Science ®Google Scholar
• Warnock DW. Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi48(1), 1–12 (2007).
   PubMedGoogle Scholar
• Denning DW, Marinus A, Cohen J et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J. Infect.37(2), 173–180 (1998).
   PubMed Web of Science ®Google Scholar
• Kami M. Current approaches to diagnose invasive aspergillosis: application of real-time automated polymerase chain reaction. Nippon Ishinkin Gakkai Zasshi42(4), 181–188 (2001).
   PubMedGoogle Scholar
• Kami M, Tanaka Y, Kanda Y et al. Computed tomographic scan of the chest, latex agglutination test and plasma (1–3)-β-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. Haematologica85(7), 745–752 (2000).
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood100(13), 4358–4366 (2002).
   PubMed Web of Science ®Google Scholar
• Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood102(3), 827–833 (2003).
   PubMed Web of Science ®Google Scholar
• Montagna D, Locatelli F, Moretta A et al. T lymphocytes of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantation. Blood103(11), 4322–4329 (2004).
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood96(6), 2055–2061 (2000).
   PubMed Web of Science ®Google Scholar
• Mahfouz T, Anaissie E. Invasive fungal infections: new development in prevention, diagnosis and management. In: Hematology 2003. American Society for Microbiology, Washington, DC, USA 445–458 (2003).
   Google Scholar
• Nucci M, Marr KA. Emerging fungal diseases. Clin. Infect. Dis.41(4), 521–526 (2005).
   PubMed Web of Science ®Google Scholar
• Vigouroux S, Morin O, Moreau P et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin. Infect. Dis.40(4), e35–e37 (2005).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case–control observational study of 27 recent cases. J. Infect. Dis.191(8), 1350–1360 (2005).
   PubMed Web of Science ®Google Scholar
• Uzun O, Anaissie E. Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. Blood86(6), 2063–2072 (1995).
   PubMed Web of Science ®Google Scholar
• Robenshtok E, Gafter-Gvili A, Goldberg E et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J. Clin. Oncol.25(34), 5471–5489 (2007).
   PubMed Web of Science ®Google Scholar
• Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol. Blood Marrow Transplant6(6a), 659–713; 715; 717–727 (2000).
   PubMed Web of Science ®Google Scholar
• Imataki O, Kami M, Kim SW et al. A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in Japan. Bone Marrow Transplant.33(12), 1173–1179 (2004).
   PubMed Web of Science ®Google Scholar
• Barker JN, Hough RE, van Burik JA et al. Serious infections after unrelated donor transplantation in 136 children: impact of stem cell source. Biol. Blood Marrow Transplant11(5), 362–370 (2005).
   PubMed Web of Science ®Google Scholar
• Miyakoshi S, Kusumi E, Matsumura T et al. Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases. Biol. Blood Marrow Transplant13(7), 771–777 (2007).
   PubMed Web of Science ®Google Scholar
• Parody R, Martino R, Rovira M et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol. Blood Marrow Transplant12(7), 734–748 (2006).
   PubMed Web of Science ®Google Scholar
• Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis.32(5), 686–693 (2001).
   PubMed Web of Science ®Google Scholar
• Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis.22(Suppl. 2), S133–S144 (1996).
   PubMed Web of Science ®Google Scholar
• Tollemar J, Ringden O. Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Drug Saf.13(4), 207–218 (1995).
   PubMed Web of Science ®Google Scholar
• Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis.27(3), 603–618 (1998).
   PubMed Web of Science ®Google Scholar
• Leenders AC, Daenen S, Jansen RL et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br. J. Haematol.103(1), 205–212 (1998).
   PubMed Web of Science ®Google Scholar
• Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl. Infect. Dis.1(4), 273–283 (1999).
   PubMedGoogle Scholar
• Tollemar J, Ringden O, Andersson S et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant.12(6), 577–582 (1993).
   PubMed Web of Science ®Google Scholar
• Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant.23(2), 163–168 (1999).
   PubMed Web of Science ®Google Scholar
• Penack O, Schwartz S, Martus P et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann. Oncol.17(8), 1306–1312 (2006).
   PubMed Web of Science ®Google Scholar
• Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med.330(4), 263–272 (1994).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ et al. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn. Microbiol. Infect. Dis.33(4), 217–222 (1999).
   PubMed Web of Science ®Google Scholar
• Wingard JR, Merz WG, Rinaldi MG et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med.325(18), 1274–1277 (1991).
   PubMed Web of Science ®Google Scholar
• Persons DA, Laughlin M, Tanner D et al. Fluconazole and Candida krusei fungemia. N. Engl. J. Med.325(18), 1315 (1991).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bohme A, Buchheidt D et al. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann. Hematol.82(Suppl. 2), S186–S200 (2003).
   PubMed Web of Science ®Google Scholar
• Abbas J, Bodey GP, Hanna HA et al.Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch. Intern. Med.160(17), 2659–2664 (2000).
   PubMed Web of Science ®Google Scholar
• Winston DJ, Chandrasekar PH, Lazarus HM et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial [see comments]. Annals of Internal Medicine, 118(7), 495–503 (1993).
   PubMed Web of Science ®Google Scholar
• Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med.326(13), 845–851 (1992).
   PubMed Web of Science ®Google Scholar
• Denning DW, Hanson LH, Perlman AM, Stevens DA. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn. Microbiol. Infect. Dis.15(1), 21–34 (1992).
   PubMed Web of Science ®Google Scholar
• Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind study. J. Infect. Dis.171(6), 1545–1552 (1995).
   PubMed Web of Science ®Google Scholar
• Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J. Infect. Dis.172(4), 1035–1041 (1995).
   PubMed Web of Science ®Google Scholar
• Rotstein C, Bow EJ, Laverdiere M et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin. Infect. Dis.28(2), 331–340 (1999).
   PubMed Web of Science ®Google Scholar
• Ninane J. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group. Eur. J. Clin. Microbiol. Infect. Dis.13(4), 330–337 (1994).
   PubMed Web of Science ®Google Scholar
• Menichetti F, Del Favero A, Martino P et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann. Intern. Med.120(11), 913–918 (1994).
   PubMed Web of Science ®Google Scholar
• Kern W, Behre G, Rudolf T et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized Phase III study. German AML Cooperative Group. Cancer83(2), 291–301 (1998).
   PubMed Web of Science ®Google Scholar
• Ellis ME, Clink H, Ernst P et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur. J. Clin. Microbiol. Infect. Dis.13(1), 3–11 (1994).
   PubMed Web of Science ®Google Scholar
• Egger T, Gratwohl A, Tichelli A et al. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study. Support Care Cancer3(2), 139–146 (1995).
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Gatny CM. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Bone Marrow Transplantation Team. Chemotherapy40(2), 136–143 (1994).
   PubMed Web of Science ®Google Scholar
• Akiyama H, Mori S, Tanikawa S, Sakamaki H, Onozawa Y. Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies. Mycoses36(11–12), 373–378 (1993).
   PubMed Web of Science ®Google Scholar
• Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann. Intern. Med.138(9), 705–713 (2003).
   PubMed Web of Science ®Google Scholar
• Young GA, Bosly A, Gibbs DL, Durrant S. A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia. Antifungal Prophylaxis Study Group. Eur. J. Cancer.35(8), 1208–1213 (1999).
   PubMed Web of Science ®Google Scholar
• Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N. Engl. J. Med.338(14), 962–968 (1998).
   PubMed Web of Science ®Google Scholar
• Kanda Y, Hamaki T, Yamamoto R et al. The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: an overview of 2483 patients from 22 studies. Cancer88(11), 2529–2533 (2000).
   PubMed Web of Science ®Google Scholar
• Bow EJ, Laverdiere M, Lussier N et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer94(12), 3230–3246 (2002).
   PubMed Web of Science ®Google Scholar
• Van Cutsem J, Van Gerven F, Van de Ven MA, Borgers M, Janssen PA. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob. Agents Chemother.26(4), 527–534 (1984).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Viviani MA, Arathoon E et al. New targets and delivery systems for antifungal therapy. Med. Mycol.38(Suppl. 1), 335–347 (2000).
   PubMed Web of Science ®Google Scholar
• Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J. Antimicrob. Chemother.26(4), 561–566 (1990).
   PubMed Web of Science ®Google Scholar
• Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet357(9270), 1766–1767 (2001).
   PubMed Web of Science ®Google Scholar
• Boogaerts MA, Verhoef GE, Zachee P et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses32(Suppl. 1), 103–108 (1989).
   PubMed Web of Science ®Google Scholar
• Heykants J, Van Peer A, Van de Velde V et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses32(Suppl. 1), 67–87 (1989).
   PubMed Web of Science ®Google Scholar
• Vandewoude K, Vogelaers D, Decruyenaere J et al. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob. Agents Chemother.41(12), 2714–2718 (1997).
   PubMed Web of Science ®Google Scholar
• Zhou H, Goldman M, Wu J et al. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J. Clin. Pharmacol.38(7), 593–602 (1998).
   PubMed Web of Science ®Google Scholar
• Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin. Microbiol. Rev.12(1), 40–79 (1999).
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Yu CY. Voriconazole against fluconazole-susceptible and resistant Candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. J. Antimicrob. Chemother.42(2), 253–256 (1998).
   PubMed Web of Science ®Google Scholar
• Denning DW, Venkateswarlu K, Oakley KL et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother.41(6), 1364–1368 (1997).
   PubMed Web of Science ®Google Scholar
• McGinnis MR, Pasarell L, Sutton DA et al.In vitro activity of voriconazole against selected fungi. Med. Mycol.36(4), 239–242 (1998).
   PubMed Web of Science ®Google Scholar
• Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J. Clin. Microbiol.37(12), 3946–3951 (1999).
   PubMed Web of Science ®Google Scholar
• Huijgens PC, Simoons-Smit AM, van Loenen AC et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato–oncology. J. Clin. Pathol.52(5), 376–380 (1999).
   PubMed Web of Science ®Google Scholar
• Kaptan K, Ural AU, Cetin T et al. Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia. J Infect. Chemother.9(1), 40–45 (2003).
   PubMedGoogle Scholar
• Nucci M, Biasoli I, Akiti T et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin. Infect. Dis.30(2), 300–305 (2000).
   PubMed Web of Science ®Google Scholar
• Vreugdenhil G, Van Dijke BJ, Donnelly JP et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk. Lymphoma11(5–6), 353–358 (1993).
   PubMed Web of Science ®Google Scholar
• Boogaerts M, Maertens J, van Hoof A et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J. Antimicrob. Chemother.48(1), 97–103 (2001).
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Dekker AW, Stamatoullas-Bastard A et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob. Agents Chemother.44(7), 1887–1893 (2000).
   PubMed Web of Science ®Google Scholar
• Lass-Florl C, Gunsilius E, Gastl G et al. Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution. Ann. Hematol.82(9), 565–569 (2003).
   PubMed Web of Science ®Google Scholar
• Menichetti F, Del Favero A, Martino P et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell’ Adulto. Clin. Infect. Dis.28(2), 250–255 (1999).
   PubMed Web of Science ®Google Scholar
• Morgenstern GR, Prentice AG, Prentice HG et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. UK Multicentre Antifungal Prophylaxis Study Group. Br. J. Haematol.105(4), 901–911 (1999).
   PubMed Web of Science ®Google Scholar
• Annaloro C, Oriana A, Tagliaferri E et al. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica80(6), 512–517 (1995).
   PubMed Web of Science ®Google Scholar
• Marr KA, Crippa F, Leisenring W et al. Itraconazle versus fluconazole for prevention of fungal infection in allogeneic HSCT recipients: results of randomized trial. Blood100, 215a (2002).
   Web of Science ®Google Scholar
• Glasmacher A, Prentice A, Gorschluter M et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J. Clin. Oncol.21(24), 4615–4626 (2003).
   PubMed Web of Science ®Google Scholar
• Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood103(4), 1527–1533 (2004).
   PubMed Web of Science ®Google Scholar
• Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol.52(4), 349–355 (2001).
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob. Agents Chemother.46(9), 3091–3093 (2002).
   PubMed Web of Science ®Google Scholar
• Romero AJ, Pogamp PL, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin. Pharmacol. Ther.71(4), 226–234 (2002).
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol.36(1), 198–202 (1998).
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis.17(8), 573–575 (1998).
   PubMed Web of Science ®Google Scholar
• Lozano-Chiu M, Arikan S, Paetznick VL, Anaissie EJ, Rex JH. Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility. J. Clin. Microbiol.37(9), 2755–2759 (1999).
   PubMed Web of Science ®Google Scholar
• Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother.46(5), 1581–1582 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med.346(4), 225–234 (2002).
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med.347(6), 408–415 (2002).
   PubMed Web of Science ®Google Scholar
• Patterson TF, Boucher HW, Herbrecht R et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin. Infect. Dis.41(10), 1448–1452 (2005).
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for Candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet366(9495), 1435–1442 (2005).
   PubMed Web of Science ®Google Scholar
• Wingard JR, Carter SL, Walsh TJ et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. ASH Annual Meeting Abstracts110(11), 163 (2007).
   Google Scholar
• Cacciapuoti A, Loebenberg D, Corcoran E et al.In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob. Agents Chemother.44(8), 2017–2022 (2000).
   PubMed Web of Science ®Google Scholar
• Uchida K, Yokota N, Yamaguchi H. In vitro antifungal activity of posaconazole against various pathogenic fungi. Int. J. Antimicrob. Agents18(2), 167–172 (2001).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother.46(4), 1032–1037 (2002).
   PubMed Web of Science ®Google Scholar
• Oakley KL, Moore CB, Denning DW. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob. Agents Chemother.41(5), 1124–1126 (1997).
   PubMed Web of Science ®Google Scholar
• Lozano-Chiu M, Arikan S, Paetznick VL et al. Treatment of murine fusariosis with SCH 56592. Antimicrob. Agents Chemother.43(3), 589–591 (1999).
   PubMed Web of Science ®Google Scholar
• Manavathu EK, Abraham OC, Chandrasekar PH. Isolation and In vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus. Clin. Microbiol. Infect.7(3), 130–137 (2001).
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med.356(4), 335–347 (2007).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med.356(4), 348–359 (2007).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis.44(1), 2–12 (2007).
   PubMed Web of Science ®Google Scholar
• Tawara S, Ikeda F, Maki K et al.In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother.44(1), 57–62 (2000).
   PubMed Web of Science ®Google Scholar
• Mikamo H, Sato Y, Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J. Antimicrob. Chemother.46(3), 485–487 (2000).
   PubMed Web of Science ®Google Scholar
• Uchida K, Nishiyama Y, Yokota N, Yamaguchi H. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J. Antibiot. (Tokyo)53(10), 1175–1181 (2000).
   PubMed Web of Science ®Google Scholar
• Watabe E, Nakai T, Matsumoto S, Ikeda F, Hatano K. Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob. Agents Chemother.47(6), 1995–1998 (2003).
   PubMed Web of Science ®Google Scholar
• Nakai T, Uno J, Otomo K et al.In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy48(2), 78–81 (2002).
   PubMed Web of Science ®Google Scholar
• Sirohi B, Powles RL, Chopra R et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant.38(1), 47–51 (2006).
   PubMed Web of Science ®Google Scholar
• Kohno S, Masaoka T, Yamaguchi H et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand. J. Infect. Dis.36(5), 372–379 (2004).
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis.24(10), 654–661 (2005).
   PubMed Web of Science ®Google Scholar
• de Wet NT, Bester AJ, Viljoen JJ et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol. Ther.21(7), 899–907 (2005).
   PubMed Web of Science ®Google Scholar
• Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for Candidaemia and invasive candidosis: a Phase III randomised double-blind trial. Lancet369(9572), 1519–1527 (2007).
   PubMed Web of Science ®Google Scholar
• van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis.39(10), 1407–1416 (2004).
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis.39(11), 1563–1571 (2004).
   PubMed Web of Science ®Google Scholar
• Kartsonis NA, Saah AJ, Joy Lipka C, Taylor AF, Sable CA. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J. Infect.50(3), 196–205 (2005).
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med.347(25), 2020–2029 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med.351(14), 1391–1402 (2004).
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Alvarado G, Giles FJ et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob. Agents Chemother.50(1), 143–147 (2006).
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med.356(24), 2472–2482 (2007).
   PubMed Web of Science ®Google Scholar
• Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis.2(2), 73–85 (2002).
   PubMed Web of Science ®Google Scholar